Searchable abstracts of presentations at key conferences in endocrinology

ea0055wc2 | Workshop C: Disorders of the thyroid gland (I) | SFEEU2018

Toxic nodule: wait or treat?

Hafeez Saba , Kumar Rakshit , Velusamy Anand , Powrie Jake , Carroll Paul

68 years old female initially referred to endocrine clinic in November 2016 for assessment of fluctuating thyroid function. She had a history of long standing primary hypothyroidism, stable on treatment with 100 mcg Levothyroxine. In last one year, Levothyroxine was tapered and stopped due to persistent suppression of TSH and high normal Free T4. Last tests showed TSH of <0.01mIU/l and Free T4 of 27.1 pmol/l. She had ongoing complaints of feeling increasingly tired and gen...

ea0038p50 | Clinical practice/governance and case reports | SFEBES2015

Early post-operative aldosterone concentration can be used to assess outcome from adrenalectomy in aldosterone producing adenoma

Baig Irfan , McGowan Barbara , Powrie Jake , Hubbard Jonathan , Carroll Paul

Introduction: Primary hyperaldosteronism (PHA) accounts for 5–13% of all hypertension and up to 20% of resistant hypertension. Aldosterone producing adenomas (APA) account for 60% of PHA and surgical resection in these patients can be curative. There is no consensus on the need for and duration of follow-up after adrenalectomy. This study assessed the immediate effect of unilateral adrenalectomy for APA on the serum potassium, renin and aldosterone levels. Acute effects o...

ea0034p404 | Thyroid | SFEBES2014

Thyroid nodules: Is one robust Thy2 result sufficient?

Joharatnam Jalini , Ngu Rose , Chandra Ash , Powrie Jake

Introduction: Approximately 400 thyroid fine needle aspirates (FNAs) are performed annually at our institution. Many are repeat aspirates of Thy2 results. Current British Thyroid Association (BTA) and Royal College of Pathologists (RCPath) guidelines recommend two FNAs performed at least 6 months apart to confirm a benign result. Our aim was to investigate whether one Thy2 result is sufficient to confirm benign pathology.Method: A retrospective analysis ...

ea0028p53 | Clinical practice/governance and case reports | SFEBES2012

Antiphospholipid syndrome and adrenal insufficiency: a case series

Whyte Martin , Grove Grace , McGowan Barbara , Carroll Paul , Powrie Jake

Introduction: Antiphospholipid syndrome (APS) is the association of anti-cardiolipin antibodies and venous & arterial thrombosis. APS accounts for <0.5% of cases of hypoadrenalism. We present a series of 5 such cases occurring at our institution plus a further patient identified with unilateral adrenal haemorrhage. Case 1 presented with nausea, vomiting and weight loss. Lupus anticoagulant positive. Commenced aspirin 300 mg. 6-weeks later represented with dehydration, ...

ea0028p159 | Nursing practise | SFEBES2012

Evaluation of a nurse-led telephone consultation service for adults with Hyperthyroidism due to Graves’ disease

Breen Louise , Powrie Jake , Kariyawasam Dulmini , Betal Dipannita , Carroll Paul

Hyperthyroidism due to Graves’ disease (GD) is traditionally managed in the secondary care ambulatory setting. Conventionally patients are required to attend for regular review at 4–12 weekly intervals, presenting practical difficulties for many adults. Nurse-led Telephone Consultations are gaining momentum in the care of long-term conditions. This Service Development Project (SDP) addressed whether or not a specialist nurse delivered telephone consultation could be ...

ea0025p37 | Clinical biochemistry | SFEBES2011

Polycythaemia in men treated with transdermal and intramuscular testosterone

Agustsson Tomas , McGowan Barbara , Powrie Jake , Thomas Stephen , Carroll Paul

Background: Testosterone replacement therapy has been shown to produce a wide range of benefits for men with hypogonadism with studies showing improvement in libido, bone density, muscle mass, body composition, mood, cognition, and erythopoiesis. The risks associated with testosterone replacement therapy are less well characterised and there is a lack of larger randomised trials. One recognised risk is polycythaemia. The aim of this study is to assess the frequency of polycyth...

ea0021p265 | Pituitary | SFEBES2009

Gender differences in presentation and response to treatment for prolactin-secreting adenoma

Luck Sara , Carroll Paul , Powrie Jake , McGowan Barbara , Thomas Stephen

Context: Prolactinomas are the most common functioning pituitary adenomas & it is recognised that gender has an influence on presentation and management of this condition.Objective: To examine the effects of gender on presentation and response to treatment in a large cohort of adults with confirmed prolactinoma (MRI performed and macroprolactin excluded).Design & patients: This retrospective cohort study design used an elec...

ea0015p88 | Clinical practice/governance and case reports | SFEBES2008

Experience from the first two years of a dedicated clinic for adults with Turner syndrome

Doherty Emma , Powrie Jake , Thomas Stephen , Brackenridge Anna , Carroll Paul

Recently updated international guidelines recommend specialist surveillance of adults with Turner Syndrome (TS). In 2005, we established a dedicated TS clinic, attracting referrals from our general endocrine service and other specialities including primary care.Twenty-three patients currently attend of whom 9 were previously under endocrinology review. Karyotypes include 45XO (8/23), 45XO/46XrX (4/23), and 45XO/46XiXq (3/23). Mean (±S.D.</sma...

ea0052p05 | (1) | UKINETS2017

Incidence of PCC/PGL in mutation positive family members at first contact

AhmedMohammed Isra , Velusamy Anand , McGowan Barbara , Izatt Louise , Powrie Jake , Obholzer Rupert , Carroll Paul

SDH mutations that contribute 15%–20% of PCC/PGL syndromes predispose to the development of tumours that originate from Adrenal, Parasympathetic and extra-adrenal sympathetic-associated chromaffin tissues. We conducted a retrospective analysis to identify the prevalence of PCC/PGL and elevated biomarkers during initial screening in patients newly identified as carrying a pathogenic SDH mutation.Method: Data collection from our random cohort of patie...

ea0046p27 | (1) | UKINETS2016

Modality to detect pancreatic NETS in MEN1: EUS or MRI?

Joshi Mamta , McGowan Barbara , Powrie Jake , Breen Louise , Jacques Audrey , Izatt Louise , Carroll Paul

Background: Pancreatic neuroendocrine tumours (pNETs) are commonly reported in patients with MEN1. The estimated incidence is reported as 40–80% of adults with MEN1 and pNETs are frequently multifocal. Guidelines recommend that CT, MRI and endoscopic ultrasound (EUS) can be used for detection and surveillance of pNETs in MEN1. MRI has been the most commonly used modality, but EUS may be more sensitive in detecting pNETs.Objective: To compare the sen...